OGEN Oragenics Inc
- Stocks
- Healthcare
- NYSEAMERICAN: OGEN
Price (delayed)
$1.115
Market cap
$4.6M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$21.4
Enterprise value
$5.63M
Relative Growth:
Rel. Growth:
22
Relative Strength:
Rel. Strength:
2
Relative Valuation:
Rel. Valuation:
N/A
Relative Profitability:
Rel. Profitability:
8
Oragenics, Inc. is focused on the creation of the Terra CoV-2 vaccine candidate to combat the novel coronavirus pandemic and the further development of effective treatments for novel antibiotics against
Highlights
OGEN's EPS has surged by 91% year-on-year and by 36% since the previous quarter
Oragenics's net income has increased by 47% YoY
The gross profit has dropped by 100% year-on-year
Oragenics's revenue has shrunk by 100% YoY
Key stats
What are the main financial stats of OGEN
Market
Valuations
Earnings
Shares outstanding
4.13M
Market cap
$4.6M
Enterprise value
$5.63M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
PEG
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$9.53M
Net income
-$10.3M
EBIT
-$9.51M
EBITDA
-$9.51M
Free cash flow
-$7.42M
Per share
Balance sheet
Liquidity
EPS
-$21.4
EPS diluted
-$21.4
Free cash flow per share
-$10.13
Book value per share
-$2.97
Revenue per share
$0
TBVPS
$2.92
Total assets
$2.14M
Total liabilities
$4.27M
Debt
$3M
Equity
-$2.13M
Working capital
-$2.13M
Debt to equity
-1.41
Current ratio
0.5
Quick ratio
0.46
Net debt/EBITDA
-0.11
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-324.8%
Return on equity
-4,705.4%
Return on invested capital
N/A
Return on capital employed
N/A
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
OGEN stock price
How has the Oragenics stock price performed over time
Intraday
-2.19%
1 week
-9.35%
1 month
-14.23%
1 year
-88.16%
YTD
-89.94%
QTD
-14.89%
Financial performance
How have Oragenics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$9.53M
Net income
-$10.3M
Gross margin
N/A
Net margin
N/A
The gross profit has dropped by 100% year-on-year
Oragenics's revenue has shrunk by 100% YoY
OGEN's operating income has surged by 52% year-on-year and by 6% since the previous quarter
Oragenics's net income has increased by 47% YoY
Price vs fundamentals
How does OGEN's price correlate with its fundamentals
Growth
What is Oragenics's growth rate over time
Valuation
What is Oragenics stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
OGEN's EPS has surged by 91% year-on-year and by 36% since the previous quarter
Oragenics's revenue has shrunk by 100% YoY
Efficiency
How efficient is Oragenics business performance
OGEN's ROA is up by 20% year-on-year but it is down by 4.2% since the previous quarter
Dividends
What is OGEN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for OGEN.
Financial health
How did Oragenics financials performed over time
The total assets is 50% less than the total liabilities
Oragenics's current ratio has shrunk by 57% YoY and by 52% QoQ
The company's quick ratio has shrunk by 53% YoY and by 50% QoQ
OGEN's debt to equity has shrunk by 108% QoQ
The debt is up by 17% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.